Healthcare

Chimeric Therapeutics Ltd (ASX:CHM) has reported encouraging early efficacy data from the highest dose cohort of its Phase 1/2 CDH17 CAR-T clinical trial, with measurable tumour shrinkage observed in two patients. The update represents another milestone for the clinical-stage biotechnology company as it advances …

Elixinol Wellness Ltd (ASX:EXL) has secured a significant retail expansion for its Healthy Chef nutrition brand through a nationwide rollout across Priceline Pharmacy stores. The agreement broadens the company's retail distribution network beyond its established direct-to-consumer and specialty retail channels. While the expanded presence …

Platformo Ltd (ASX:PFM) continues operating as a micro-cap technology company centred on its Malaysian software subsidiary, Biztrak Business Solutions. Following its 2025 rebrand from Cape Range Ltd, the company has outlined ambitions to become a broader technology platform through future acquisitions and expansion opportunities. …

Hydration Pharmaceuticals Company Limited (ASX:HPC) has undertaken a significant leadership and corporate restructuring as it seeks to strengthen its financial position and sharpen its operational focus. The company combined a modest capital raising with changes across its board and executive team, while introducing cost-saving …

HealthCo Healthcare & Wellness REIT (ASX:HCW) remained on investors' radar after a TradingView snapshot showed the units trading approximately5.7% higheron 23 July 2026, although no independently verified closing price was available. Recent attention has centred on the ongoing transition of hospitals previously operated by …

CSL Ltd (ASX:CSL) traded at AUD 116.62, down 1.12%, during the afternoon trading session on 23 July 2026. Despite its position as one of Australia's largest healthcare companies, the stock remains 56.08% lower over the past year, giving the company a market capitalisation of …

OncoSil Medical Limited (ASX:OSL) remained in the spotlight after its shares traded higher on 23 July 2026. While no confirmed company announcement was released on the day, investor attention continued to centre on updated clinical data from the company's Phase II TRIPP-FFX study, which …